At UNISKIN, skincare begins as science. We’ve built a complete research system that tracks skin aging from origin to outcome — discovering how skin ages, developing the actives that intervene, and validating every result in clinical practice. Three stages, one continuous loop.
We map skin aging at its source. UNISKIN built China’s largest skin-aging database from the ground up — 150,000+ skin profiles and 50+ aging-related gene targets — to trace the precise trajectories along which skin ages. This is the foundation everything else is built on.
We turn insight into actives. Guided by those aging trajectories, we engineer targeted functional ingredients — 72 proprietary actives to date — each designed to act on the specific biological mechanism behind a given sign of aging.
We prove it where it counts. Every formulation is tested through six years of medical-aesthetic clinical application, generating objective, statistically meaningful efficacy data — held to the same evidentiary standard as clinical medicine.
Skin research → biotechnology → clinical evidence: a closed efficacy loop, where every clinical result feeds back into the database and the science compounds with each cycle.
18 papers in leading journals, including CAS Tier-1 titles such as Advanced Functional Materials and Phytomedicine, the pharmaceutics journal Pharmaceutics, and dermatology journals Skin Research and Technology and Clinical, Cosmetic and Investigational Dermatology.
3 proprietary core technologies, backed by an IP portfolio of 21 invention patents, 2 utility-model patents, and 8 design patents.
In partnership with the Chinese Association of Plastics and Aesthetics, UNISKIN co-authored three major anti-aging standards — including the PDRN group standard published in January 2026.
An internal R&D team and an external advisory board work in parallel — long-term collaborations with Huashan Hospital Dermatology, J&J JLABS, and other academic and industry institutions.
Joint research with the Nobel-laureate intelligent-new-materials team at Harbin Institute of Technology (Shenzhen) — focused on precision delivery of bioactives and a next-generation intelligent nano-carrier system.
Deep analysis of the underlying mechanisms of skin aging and barrier imbalance — from inflammation, immunity, and cellular energy to structural support — building a multi-dimensional efficacy evaluation framework.
Formula design built on biopharmaceutical principles — engineering stable, structurally precise, high-performing actives, paired with clinical-grade efficacy validation systems.
